ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Tanveer A. Khan
Pierre Voisine
Frank W. Sellke
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, T. A.
Right arrow Articles by Sellke, F. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khan, T. A.
Right arrow Articles by Sellke, F. W.
Related Collections
Right arrow Cardiac - pharmacology

Ann Thorac Surg 2005;79:1545-1550
© 2005 The Society of Thoracic Surgeons


Original articles: Cardiovascular

Aprotinin Inhibits Protease-Dependent Platelet Aggregation and Thrombosis

Tanveer A. Khan, MD, Cesario Bianchi, MD, PhD, Pierre Voisine, MD, Jennifer Sandmeyer, BS, Jun Feng, MD, PhD, Frank W. Sellke, MD*

Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Accepted for publication November 10, 2004.

* Address reprint requests to Dr Sellke, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, 110 Francis Street, LMOB Suite 2A, Boston, MA 02215 (E-mail: fsellke{at}caregroup.harvard.edu).

BACKGROUND: Hemostatic effects of the protease inhibitor aprotinin in cardiac surgery are well described, and recent evidence suggests an antithrombotic mechanism of aprotinin through inhibition of thrombin-mediated platelet activation. We hypothesized that aprotinin provides hemostasis while reducing vascular thrombosis by attenuating protease-dependent platelet function.

METHODS: Rabbits (3 to 4 kg) underwent carotid artery thrombosis induced by electrical current. Treatment animals (n = 8) received aprotinin by a 100,000-KIU bolus followed by a continuous infusion (25,000 KIU/h). Control animals (n = 8) received crystalloid solution. Thrombus weight and time to thrombotic occlusion were determined. Platelet aggregation was examined in response to protease-dependent (thrombin) and protease-independent (adenosine diphosphate, ADP) platelet agonists. Platelet thrombin protease-activated receptor (PAR) expression was analyzed by Western blot. Ear bleeding time and abdominal incisional bleeding were measured at baseline and serially.

RESULTS: Thrombus weight was decreased by aprotinin (6.1 ± 1.1 mg versus 10.8 ± 1.5 mg, aprotinin versus control, p < 0.05). Time to thrombotic occlusion was prolonged in the aprotinin group (17.4 ± 1.0 minutes versus 8.3 ± 1.3 minutes, p < 0.001). Rabbit platelet expression of thrombin PARs was demonstrated by Western blot analysis, and was not altered by aprotinin therapy. Platelet aggregation due to thrombin was decreased by aprotinin therapy (59.2% ± 3.0% versus 95.8% ± 1.5%, p < 0.001), whereas protease-independent, ADP-induced platelet aggregation was unchanged with aprotinin. Incisional bleeding was not different between groups. In the aprotinin group, bleeding time was unchanged at baseline and then reduced for the duration of the experiment (35.0 ± 4.7 seconds versus 76.8 ± 6.4 seconds, p < 0.05).

CONCLUSIONS: While providing hemostatic effects, aprotinin attenuates vascular thrombosis in part by inhibition of PAR activation, resulting in the prevention of thrombin-induced platelet aggregation.




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
P. H. Desai, D. Kurian, N. Thirumavalavan, S. P. Desai, P. Ziu, M. Grant, C. White, R. C. Landis, and R. S. Poston
A Randomized Clinical Trial Investigating the Relationship Between Aprotinin and Hypercoagulabilityin Off-Pump Coronary Surgery
Anesth. Analg., November 1, 2009; 109(5): 1387 - 1394.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
A. M. Mengistu, K. D. Rohm, J. Boldt, J. Mayer, S. W. Suttner, and S. N. Piper
The Influence of Aprotinin and Tranexamic Acid on Platelet Function and Postoperative Blood Loss in Cardiac Surgery
Anesth. Analg., August 1, 2008; 107(2): 391 - 397.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
Z. N. Kon, E. N. Brown, M. C. Grant, T. Ozeki, N. S. Burris, M. J. Collins, M. H. Kwon, and R. S. Poston
Warm ischemia provokes inflammation and regional hypercoagulability within the heart during off-pump coronary artery bypass: a possible target for serine protease inhibition
Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 215 - 221.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. R.S. Day, D. O. Haskard, K. M. Taylor, and R. C. Landis
Effect of Aprotinin and Recombinant Variants on Platelet Protease-Activated Receptor 1 Activation
Ann. Thorac. Surg., February 1, 2006; 81(2): 619 - 624.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. R.S. Day, K. M. Taylor, E. A. Lidington, J. C. Mason, D. O. Haskard, A. M. Randi, and R. C. Landis
Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1
J. Thorac. Cardiovasc. Surg., January 1, 2006; 131(1): 21 - 27.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.